phillygenin: cytoprotective lignan from Forsythia suspensa; structure in first source [MeSH]
ID Source | ID |
---|---|
PubMed CID | 3083590 |
CHEMBL ID | 2260010 |
SCHEMBL ID | 10052265 |
MeSH ID | M0537666 |
Synonym |
---|
phenol, 4-(4-(3,4-dimethoxyphenyl)tetrahydro-1h,3h-furo(3,4-c)furan-1-yl)-2-methoxy-, (1s-(1alpha,3aalpha,4beta,6aalpha))- |
unii-886ial08gn |
phillygenol |
epipinoresinol methyl ether |
phillygenin |
487-39-8 |
886ial08gn , |
ACON1_001142 |
sylvatesmin |
MEGXP0_000876 |
NCGC00169636-01 |
BRD-K69431605-001-01-7 |
4-[(3s,3ar,6r,6ar)-6-(3,4-dimethoxyphenyl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenol |
S9187 |
(+)-monomethylpinoresinol |
(+)-phillygenin |
phillyrin aglycone |
phenol, 4-((1s,3ar,4r,6ar)-4-(3,4-dimethoxyphenyl)tetrahydro-1h,3h-furo(3,4-c)furan-1-yl)-2-methoxy- |
CHEMBL2260010 |
SCHEMBL10052265 |
AC-34423 |
Q-100547 |
DTXSID80197588 |
CS-5705 |
HY-N0483 |
AKOS030524964 |
4-((1s,3ar,4r,6ar)-4-(3,4-dimethoxyphenyl)tetrahydro-1h,3h-furo[3,4-c]furan-1-yl)-2-methoxyphenol |
mfcd01075148 |
forsythigenol |
CCG-268325 |
Q27269895 |
(+)-sylvatesmin |
AS-56623 |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1371010 | Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 ISSN: 1520-6025 | Chemical Constituents and Anti-inflammatory Principles from the Fruits of Forsythia suspensa. |
AID1371011 | Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 ISSN: 1520-6025 | Chemical Constituents and Anti-inflammatory Principles from the Fruits of Forsythia suspensa. |
AID1371012 | Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction at 10 ug/ml incubated for 5 mins before fMLP/CB stimulation | 2017 | Journal of natural products, 04-28, Volume: 80, Issue:4 ISSN: 1520-6025 | Chemical Constituents and Anti-inflammatory Principles from the Fruits of Forsythia suspensa. |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (9.52) | 29.6817 |
2010's | 7 (33.33) | 24.3611 |
2020's | 12 (57.14) | 2.80 |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (4.55%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 21 (95.45%) | 84.16% |
Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ursolic acid | hydroxy monocarboxylic acid; pentacyclic triterpenoid | geroprotector; plant metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
pinoresinol | pinoresinol | hypoglycemic agent; phytoestrogen; plant metabolite | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
matairesinol | gamma-lactone; lignan; polyphenol | angiogenesis inhibitor; anti-asthmatic agent; phytoestrogen; plant metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
oleanolic acid 3-acetate | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |||
sorafenib | (trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide | angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
epipinoresinol | pinoresinol | marine metabolite; plant metabolite | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
forsythiaside | hydroxycinnamic acid | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Ache | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Acute Lung Injury | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Anasarca | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Cancer of Esophagus | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
Cirrhosis, Liver | 0 | 2020 | 2023 | 2.3 | low | 0 | 0 | 0 | 0 | 1 | 2 | |
Colitis | 0 | 2022 | 2023 | 1.5 | low | 0 | 0 | 0 | 0 | 0 | 2 | |
Colitis Gravis | 0 | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Colitis, Ulcerative | 0 | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Coronavirus Infections | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Disease Models, Animal | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Edema | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Esophageal Neoplasms | 0 | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
Fatty Liver, Nonalcoholic | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Hepatitis | 0 | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
Infections, Coronavirus | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Inflammation | 0 | 2021 | 2023 | 2.2 | medium | 0 | 0 | 0 | 0 | 0 | 5 | |
Innate Inflammatory Response | 0 | 2021 | 2023 | 2.2 | medium | 0 | 0 | 0 | 0 | 0 | 5 | |
Liver Cirrhosis | 0 | 2020 | 2023 | 2.3 | low | 0 | 0 | 0 | 0 | 1 | 2 | |
Lung Injury, Acute | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Metastase | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Neoplasm Metastasis | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Non-alcoholic Fatty Liver Disease | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Osteogenic Sarcoma | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Osteosarcoma | 0 | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Pain | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 | |
Poultry Diseases | 0 | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
Article | Year |
---|---|
Determination of phillygenin in rat plasma by high-performance liquid chromatography and its application to pharmacokinetic studies. European journal of drug metabolism and pharmacokinetics, , Volume: 38, Issue:3 | 2013 |